Log on / register
Feedback | Support | My details
Potential cellular conformations of the CCN3(NOV) protein.
Kyurkchiev S, Yeger H, Bleau AM, Perbal B
Cell Commun Signal 2004 Sep 10, 2:9
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
What's in an intron? CCN1 mRNA splicing in cancer.
Leask A
J Cell Commun Signal 2009 Jun, 3:151-152
 [PubMed Central] [PubMed] [Related articles]
2.
Domain-specific CCN3 antibodies as unique tools for structural and functional studies.
Lazar N, Manara C, Navarro S, Bleau AM, Llombart-Bosch A, Scotlandi K, Planque N, Perbal B
J Cell Commun Signal 2007 Sep, 1:91-102
 [PubMed Central] [PubMed] [Related articles]
3.
CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.
Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC
Am J Pathol 2009 May, 174:1725-34
 [PubMed Central] [PubMed] [Related articles]
4.
*** Unable to retrieve article 19381874 ***

 [PubMed Central] [PubMed] [Related articles]
5.
Alternative splicing of CCN mRNAs .... it has been upon us.
Perbal B
J Cell Commun Signal 2009 Jun, 3:153-7
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 3 articles in BioMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.